Roche Launches New DNA Sequencing Platform AXELIOS 1
Roche has launched AXELIOS 1, a single-molecule sequencing platform that uses sequencing by expansion technology to deliver same-day whole-genome results.
Roche has launched AXELIOS 1, a single-molecule sequencing platform that uses sequencing by expansion technology to deliver same-day whole-genome results.
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
The updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.
The test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
Read MoreThe new 3B-NEO service uses whole exome and whole genome sequencing to identify risks for serious childhood-onset disorders before symptoms appear.
Read MoreClinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read MoreResults from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MoreUpdated criteria integrate clinical manifestations and genetic testing to reduce the time required to reach an informed diagnosis.
Read MoreThe integrated electrophoresis solution is designed to simplify routine verification by eliminating gel casting and buffer preparation.
Read MoreThe multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read MoreThe Callisto Sample Prep System application is optimized for the PromethION platform to support whole genome sequencing workflows.
Read MoreThe settlement follows a criminal conviction and addresses more than $174 million in fraudulent Medicare claims involving multiple laboratories.
Read MoreThe funding will support commercial expansion of the company’s blood-based diagnostic tests and the appointment of a new president and chief operating officer.
Read MoreResearch presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read MoreEmerging Andes virus cases—capable of person-to-person transmission—are prompting US clinical labs to reassess hantavirus protocols and consider travel and epidemiologic exposures beyond rodent contact.
Read MoreCo-Diagnostics has completed its assay development strategy for Bundibugyo virus, following the WHO’s emergency declaration and CDC’s updated traveler screening measures amid ongoing Ebola outbreaks in the DRC and Uganda.
Read MoreThe tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read MoreThe FDA has approved Guardant360 Liquid CDx, a blood-based test that integrates genomic and epigenomic profiling for advanced cancer, offering a broader genomic footprint and faster results.
Read More